NanoViricides FY26 net loss narrows 13% to $8.22 million; revenue remains zero
NNVC•NanoViricides reported a fiscal 2026 net loss of $8.22 million, down 13%, and no revenue. Cash and cash equivalents were $2.8 million at June 30, 2026, and management flagged substantial doubt about funding for the next 12 months.
1. Annual results
For the year ended June 30, 2026, NanoViricides reported a net loss of $8.22 million, with basic and diluted loss per share improving to $0.41 from $0.63 a year earlier. Research and development expense fell 15% to $4.71 million, general and administrative costs dropped 11% to $3.6 million, and the company reported no revenue. Cash and cash equivalents totaled $2.8 million at year-end, and management flagged substantial doubt about going-concern funding for 12 months.
